Human α-defensins neutralize fibrinolytic activity exerted by staphylokinase

Summary

Defensins, cationic peptides with bacteriolytic properties, are abundantly found at inflammation sites and in human coronary vessels. Vascular occlusive diseases, such as myocardial infarction, pulmonary embolism, and peripheral arterial occlusion are presently treated by thrombolytic intervention using staphylokinase, a plasminogen activator of bacterial origin. In this study we assessed a possible interaction between defensins and staphylokinase, both molecules being present in an acutely ill patient. Using an ELISA-based system, we found that staphylokinase and defensins displayed a strong and dose-dependent binding. In contrast, urokinase, another plasminogen activator of endogenous origin, displayed only minimal binding to defensins. Next, we proved that interaction between staphylokinase and defensins led to fuctional consequences resulting in a significant decrease (p<0.002) of plasminogen activation capacity upon complex formation. In contrast, urokinase retained most of its activity even in 10-fold molar excess of defensins. Finally, we found that staphylokinase-triggered lysis of fibrin was efficiently inhibited in the presence of defensins. To assess structural requirements for staphylokinase/defensin interaction, six staphylokinase mutant variants were studied. Inactivation pattern of the tested staphylokinase variants suggested a direct binding of defensins to serine protease-like domain of staphylokinase. In conclusion, we show complex formation between staphylokinase and α-defensins resulting in a significant reduction of fibrinolytic activity. This finding may have clinical implications, since fibrinolytic effects of staphylokinase may be downregulated at the site of vascular occlusion.

Keywords

Staphylokinase - defensins

• References

• 1 Jin T, Bokarewa M, McIntyre L. et al. Fatal outcome of bacteremic patients caused by infection with staphylokinase deficient Staphylococcus aureus strains. J Med Microbiol 2003; 52: 919-23.
• 2 Collen D. Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent. Nat Med 1998; 04: 279-84.
• 3 Silence K, Hartmann M, Gührs K-H. et al. Structure-function relationships in staphylokinase as revealed by “clustered charge to alanine” mutagenesis. J Biol Chem 1995; 270: 27192-8.
• 4 Ohlenschlager O, Ramachandran R, Guhrs KH. et al. Nuclear magnetic resonance solution structure of the plasminogen-activator protein staphylokinase.PG – 10635-42. Biochemistry 1998; 37: 10635-42.
• 5 Parry MA, Fernandez-Catalan C, Bergner A. et al. The ternary microplasmin-staphylokinase-microplasmin complex is a proteinasecofactor-substrate complex in action. Nat Struct Biol 1998; 05: 917-23.
• 6 Chen Y, Song G, Jiang F. et al. Crystal structure of a staphylokinase variant: a model for reduced antigenicity. Eur J Biochem 2002; 269: 705-11.
• 7 Collen D, Moreau H, Stockx L. et al. Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization. Circulation 1996; 94: 197-206.
• 8 Laroche Y, Heymans S, Capaert S. et al. Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. Blood 2000; 96: 1425-32.
• 9 Silence K, Collen D, Lijnen HR. Interaction between staphylokinase, plasmin(ogen), and alpha 2-antiplasmin. Recycling of staphylokinase after neutralization of the plasmin-staphylokinase complex by alpha 2-antiplasmin. J Biol Chem 1993; 268: 9811-6.
• 10 Yang D, Biragyn A, Kwak LW. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol 2002; 23: 291-6.
• 11 Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-95.
• 12 Bdeir K, Cane W, Canziani G. et al. Defensin promotes the binding of lipoprotein(a) to vascular matrix. Blood 1999; 94: 2007-19.
• 13 Barnathan ES, Raghunath PN, Tomaszewski JE. et al. Immunohistochemical localization of defensin in human coronary vessels. Am J Pathol 1997; 150: 1009-20.
• 14 Ihi T, Nakazato M, Mukae H. et al. Elevated concentrations of human neutrophil peptides in plasma, blood, and body fluids from patients with infections. Clin Infect Dis 1997; 25: 1134-40.
• 15 Soong LB, Ganz T, Ellison A. et al. Purification and characterization of defensins from cystic fibrosis sputum. Inflamm Res 1997; 46: 98-102.
• 16 Bokarewa MI, Jin T, Tarkowski A. Intra-articular release and accumulation of defensins and bactericidal/permeability-increasing protein in patients with rheumatoid arthritis. J Rheumatol 2003; 30: 1719-24.
• 17 Bremell T, Lange S, Yacoub A. et al. Experimental Staphylococcus aureus arthritis in mice. Infect Immun 1991; 59: 2615-23.
• 18 Higazi AA, Barghouti II, Abu-Much R. Identification of an inhibitor of tissue-type plasminogen activator-mediated fibrinolysis in human neutrophils. A role for defensin. J Biol Chem 1995; 270: 9472-7.
• 19 Lahteenmaki K, Kuusela P, Korhonen TK. Bacterial plasminogen activators and receptors. FEMS Microbiol Rev 2001; 25: 531-52.
• 20 Jin T, Bokarewa M, Foster T. et al. Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J Immunol 2004; 172 (02) 1169-76.
• 21 Oppenheim JJ, Yang D, Biragyn A. et al. Chemokine receptors on dendritic cells promote autoimmune reactions. Arthritis Res 2002; 04: S183-S188.
• 22 Tani K. et al Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. Int Immunol 2000; 12: 691-700.
• 23 Higazi A.A.. et al. The alpha-defensins stimulate proteoglycan-dependent catabolism of low-density lipoprotein by vascular cells: a new class of inflammatory apolipoprotein and a possible contributor to atherogenesis. Blood 2000; 96: 1393-8.